A-485 suppresses p300-mediated histone acetylation and the transcription of key oncogenes such as MYC; and combination therapy with A-485 and JQ1 synergistically suppresses Wnt/β catenin pathway and c-Myc target gene expression, and synergistically induces NUT midline carcinoma cell apoptosis 103. Here, MYC is linked to carcinoma.